Written by Biogen
- Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed neurological targets
- Biogen will pay Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock
- Sangamo is eligible to receive up to $2.37 billion in potential milestones, as well as royalties on potential net commercial sales
- Biogen’s access to Sangamo’s gene regulation therapies complements its expanding efforts in gene therapy across diverse neurological diseases
CAMBRIDGE, Mass. and BRISBANE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets. The companies will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology delivered via adeno-associated virus (AAV) to modulate the expression of key genes involved in neurological diseases.
Click here to read full article.